Caroline Hroncich on Muck Rack

Caroline Hroncich

New York
As seen in: Medium, MSN, MSN Canada, MSN Singapore, Business Insider, Business Insider Singapore, Daily Mail, MSN India, Reuters, Yahoo Canada and
Principal at Line Communications. Contributor for @FinancialBrand. chroncich@linecommunicationsllc.com.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Caroline

Contact Caroline, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

10 Universities With the Best Biomedical Industry Connections

|
By Caroline Hroncich
| Cure.
A university’s connections to the biomedical industry through co-authorship of research papers is one of the strongest predictors of translational success in academia. When a corporate scientist shares author credit with a university lab, the company has typically contributed data, samples, time, or capital to make that happen.
Open in Who Shared Issue with article?

New York State Has Built One of the Country’s Most Powerful Biomedical Ecosystems

|
By Caroline Hroncich
| Cure.
Few states have built a biomedical innovation infrastructure as broad or as deep as New York's. Decades of strategic investment have produced a research network that ranks among the country's most prolific in translating science into real-world health impact.
Open in Who Shared Issue with article?

Cure's Biotech Funding Tracker 2026

|
By Caroline Hroncich
| Cure.
Coultreon Biopharma (formerly Onco3R Therapeutics) Date: April 28 Series: Series A Amount: $125M Therapeutic Area: Autoimmune disease, oncology (bladder cancer, lung cancer, solid tumors) Modality: Oral small molecule (SIK3 inhibitor) Notable Investors: Sofinnova Investments and Forbion (co-leads); Novo Holdings, Galapagos, Regeneron Ventures, Balyasny Asset Management, Luma Group, Samsara BioCapital, Longwood Fund, Finchley Healthcare Ventures Brussels-based Coultreon Biopharma—relaunched...
Open in Who Shared Issue with article?
See all 427 licensed articles (1,340 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified